GSK is increasingly confident that its anti-BCMA drug Blenrep could be returned to the US market, after revealing data from the DREAMM-8 trial of the drug in multiple myeloma at ASCO. Adding ...

GSK is hoping to leapfrog Blenrep into earlier-line therapy with the DREAMM-7 and DREAMM-8 data, and said it is looking forward to discussing the data with regulators, saying the drug could ...

GSK (GSK) announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep in combination with bortezomib plus dexamethasone as a ...

GlaxoSmithKline (GB:GSK ... s Blenrep combinations for treating relapsed multiple myeloma have been accepted for review by the US FDA, supported by promising results from the DREAMM-7 and DREAMM ...

Year to date, shares of GSK have lost 7.9% compared with the industry’s 9% decline. Image Source: Zacks Investment Research The BLA for the Blenrep combo was based on data from the III DREAMM-7 ...

British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer, at ...

GSK PLC - London-based pharmaceuticals firm - Says Dreamm-7 trial shows sustained overall survival benefit for Blenrep, the brand name of belantamab m... (Alliance News) - GSK PLC on Monday ...

a known risk of treatment with Blenrep, were generally manageable and resolvable with dose modification and led to a low (10%) treatment discontinuation rate. Price Action: GSK stock was down 1.77 ...

GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.

GSK's blood-cancer drug Blenrep showed positive overall survival data in a late-stage trial, increasing the likelihood for the treatment to return to market next year. The data showed that Blenrep ...

GSK (GSK) announced “statistically significant and clinically meaningful” overall survival results from a planned interim analysis of the DREAMM-7 trial evaluating belantamab mafodotin in ...

GSK) announced statistically significant and clinically meaningful overall survival (OS) results from a planned interim analysis of the DREAMM-7 trial. The trial assessed Blenrep (belantamab ...